Global Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Research Report 2023

Publication ID:

PB510234126

Publication Date:

October 20, 2023

Pages:

110

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

IT Services [2]

Hardware (Computing & Electronics) [3]

Computing & Electronics [4]

Description:

The global Novel Coronavirus (COVID-19) Vaccine market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Novel Coronavirus (COVID-19) Vaccine market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Novel Coronavirus (COVID-19) Vaccine market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Inovio Pharmaceuticals
Takis Biotech (Evvivax)
Zydus Cadila
Codagenix, Inc.
GeoVax, Inc.
Bravovax
Janssen Pharmaceutical Companies
Altimmune
Vaxart
CanSino Biologics
ExpreS2ion Biotechnologies ApS
Clover Biopharmaceuticals
GSK
Vaxil Bio Ltd.
Generex
Novavax, Inc.
Sanofi Pasteur
Baylor
iBio, Inc.
Moderna, Inc.
Curevac
ImmunoPrecise
Segment by Type
DNA
RNA
Others
Segment by Application
Mild Symptom Patient
Critically Ill Patient
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Novel Coronavirus (COVID-19) Vaccine report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 DNA
1.2.3 RNA
1.2.4 Others
1.3 麻豆原创 by Application
1.3.1 Global Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Mild Symptom Patient
1.3.3 Critically Ill Patient
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Perspective (2018-2029)
2.2 Novel Coronavirus (COVID-19) Vaccine Growth Trends by Region
2.2.1 Global Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Novel Coronavirus (COVID-19) Vaccine Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Novel Coronavirus (COVID-19) Vaccine Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Dynamics
2.3.1 Novel Coronavirus (COVID-19) Vaccine Industry Trends
2.3.2 Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Drivers
2.3.3 Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Challenges
2.3.4 Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Novel Coronavirus (COVID-19) Vaccine Players by Revenue
3.1.1 Global Top Novel Coronavirus (COVID-19) Vaccine Players by Revenue (2018-2023)
3.1.2 Global Novel Coronavirus (COVID-19) Vaccine Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Novel Coronavirus (COVID-19) Vaccine Revenue
3.4 Global Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Concentration Ratio
3.4.1 Global Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Novel Coronavirus (COVID-19) Vaccine Revenue in 2022
3.5 Novel Coronavirus (COVID-19) Vaccine Key Players Head office and Area Served
3.6 Key Players Novel Coronavirus (COVID-19) Vaccine Product Solution and Service
3.7 Date of Enter into Novel Coronavirus (COVID-19) Vaccine 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Novel Coronavirus (COVID-19) Vaccine Breakdown Data by Type
4.1 Global Novel Coronavirus (COVID-19) Vaccine Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Novel Coronavirus (COVID-19) Vaccine Forecasted 麻豆原创 Size by Type (2024-2029)
5 Novel Coronavirus (COVID-19) Vaccine Breakdown Data by Application
5.1 Global Novel Coronavirus (COVID-19) Vaccine Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Novel Coronavirus (COVID-19) Vaccine Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Size (2018-2029)
6.2 North America Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Size by Country (2018-2023)
6.4 North America Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Size (2018-2029)
7.2 Europe Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Size by Country (2018-2023)
7.4 Europe Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Size (2018-2029)
9.2 Latin America Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Inovio Pharmaceuticals
11.1.1 Inovio Pharmaceuticals Company Detail
11.1.2 Inovio Pharmaceuticals Business Overview
11.1.3 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Introduction
11.1.4 Inovio Pharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.1.5 Inovio Pharmaceuticals Recent Development
11.2 Takis Biotech (Evvivax)
11.2.1 Takis Biotech (Evvivax) Company Detail
11.2.2 Takis Biotech (Evvivax) Business Overview
11.2.3 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Introduction
11.2.4 Takis Biotech (Evvivax) Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.2.5 Takis Biotech (Evvivax) Recent Development
11.3 Zydus Cadila
11.3.1 Zydus Cadila Company Detail
11.3.2 Zydus Cadila Business Overview
11.3.3 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Introduction
11.3.4 Zydus Cadila Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.3.5 Zydus Cadila Recent Development
11.4 Codagenix, Inc.
11.4.1 Codagenix, Inc. Company Detail
11.4.2 Codagenix, Inc. Business Overview
11.4.3 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
11.4.4 Codagenix, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.4.5 Codagenix, Inc. Recent Development
11.5 GeoVax, Inc.
11.5.1 GeoVax, Inc. Company Detail
11.5.2 GeoVax, Inc. Business Overview
11.5.3 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
11.5.4 GeoVax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.5.5 GeoVax, Inc. Recent Development
11.6 Bravovax
11.6.1 Bravovax Company Detail
11.6.2 Bravovax Business Overview
11.6.3 Bravovax Novel Coronavirus (COVID-19) Vaccine Introduction
11.6.4 Bravovax Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.6.5 Bravovax Recent Development
11.7 Janssen Pharmaceutical Companies
11.7.1 Janssen Pharmaceutical Companies Company Detail
11.7.2 Janssen Pharmaceutical Companies Business Overview
11.7.3 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Introduction
11.7.4 Janssen Pharmaceutical Companies Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.7.5 Janssen Pharmaceutical Companies Recent Development
11.8 Altimmune
11.8.1 Altimmune Company Detail
11.8.2 Altimmune Business Overview
11.8.3 Altimmune Novel Coronavirus (COVID-19) Vaccine Introduction
11.8.4 Altimmune Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.8.5 Altimmune Recent Development
11.9 Vaxart
11.9.1 Vaxart Company Detail
11.9.2 Vaxart Business Overview
11.9.3 Vaxart Novel Coronavirus (COVID-19) Vaccine Introduction
11.9.4 Vaxart Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.9.5 Vaxart Recent Development
11.10 CanSino Biologics
11.10.1 CanSino Biologics Company Detail
11.10.2 CanSino Biologics Business Overview
11.10.3 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Introduction
11.10.4 CanSino Biologics Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.10.5 CanSino Biologics Recent Development
11.11 ExpreS2ion Biotechnologies ApS
11.11.1 ExpreS2ion Biotechnologies ApS Company Detail
11.11.2 ExpreS2ion Biotechnologies ApS Business Overview
11.11.3 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Introduction
11.11.4 ExpreS2ion Biotechnologies ApS Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.11.5 ExpreS2ion Biotechnologies ApS Recent Development
11.12 Clover Biopharmaceuticals
11.12.1 Clover Biopharmaceuticals Company Detail
11.12.2 Clover Biopharmaceuticals Business Overview
11.12.3 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Introduction
11.12.4 Clover Biopharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.12.5 Clover Biopharmaceuticals Recent Development
11.13 GSK
11.13.1 GSK Company Detail
11.13.2 GSK Business Overview
11.13.3 GSK Novel Coronavirus (COVID-19) Vaccine Introduction
11.13.4 GSK Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.13.5 GSK Recent Development
11.14 Vaxil Bio Ltd.
11.14.1 Vaxil Bio Ltd. Company Detail
11.14.2 Vaxil Bio Ltd. Business Overview
11.14.3 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Introduction
11.14.4 Vaxil Bio Ltd. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.14.5 Vaxil Bio Ltd. Recent Development
11.15 Generex
11.15.1 Generex Company Detail
11.15.2 Generex Business Overview
11.15.3 Generex Novel Coronavirus (COVID-19) Vaccine Introduction
11.15.4 Generex Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.15.5 Generex Recent Development
11.16 Novavax, Inc.
11.16.1 Novavax, Inc. Company Detail
11.16.2 Novavax, Inc. Business Overview
11.16.3 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
11.16.4 Novavax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.16.5 Novavax, Inc. Recent Development
11.17 Sanofi Pasteur
11.17.1 Sanofi Pasteur Company Detail
11.17.2 Sanofi Pasteur Business Overview
11.17.3 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Introduction
11.17.4 Sanofi Pasteur Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.17.5 Sanofi Pasteur Recent Development
11.18 Baylor
11.18.1 Baylor Company Detail
11.18.2 Baylor Business Overview
11.18.3 Baylor Novel Coronavirus (COVID-19) Vaccine Introduction
11.18.4 Baylor Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.18.5 Baylor Recent Development
11.19 iBio, Inc.
11.19.1 iBio, Inc. Company Detail
11.19.2 iBio, Inc. Business Overview
11.19.3 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
11.19.4 iBio, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.19.5 iBio, Inc. Recent Development
11.20 Moderna, Inc.
11.20.1 Moderna, Inc. Company Detail
11.20.2 Moderna, Inc. Business Overview
11.20.3 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
11.20.4 Moderna, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.20.5 Moderna, Inc. Recent Development
11.21 Curevac
11.21.1 Curevac Company Detail
11.21.2 Curevac Business Overview
11.21.3 Curevac Novel Coronavirus (COVID-19) Vaccine Introduction
11.21.4 Curevac Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.21.5 Curevac Recent Development
11.22 ImmunoPrecise
11.22.1 ImmunoPrecise Company Detail
11.22.2 ImmunoPrecise Business Overview
11.22.3 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Introduction
11.22.4 ImmunoPrecise Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.22.5 ImmunoPrecise Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Inovio Pharmaceuticals
Takis Biotech (Evvivax)
Zydus Cadila
Codagenix, Inc.
GeoVax, Inc.
Bravovax
Janssen Pharmaceutical Companies
Altimmune
Vaxart
CanSino Biologics
ExpreS2ion Biotechnologies ApS
Clover Biopharmaceuticals
GSK
Vaxil Bio Ltd.
Generex
Novavax, Inc.
Sanofi Pasteur
Baylor
iBio, Inc.
Moderna, Inc.
Curevac
ImmunoPrecise

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.